Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2075333 | 1.00 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1270160 | 1.00 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15252320 | 0.87 | CA12 (0.40) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1271451 | 0.87 | LMNA (0.47) | KDM4ELMNAGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL2075065 | 0.81 | LMNA (0.48) | KDM4ELMNAGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL2074319 | 0.81 | LMNA (0.48) | KDM4ELMNAGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL2656680 | 0.81 | LMNA (0.48) | KDM4ELMNAGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL2072339 | 0.77 | GCK (0.41) | GCK | |
| SCHEMBL2075146 | 0.77 | GCK (0.41) | GCK | |
| SCHEMBL2657926 | 0.77 | GCK (0.49) | POLBGCKKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902200-B2 | 3-[6-(Azetidine-1-carbonyl)pyridin-3-yl]oxy-5-[(3S)-1-methyl-2-oxo-pyrrolidin-3-yl]oxy-N-(5-methylpyrazin-2-yl)benzamide; activates glucokinase leading to decreased glucose threshold for insulin secretion and lowering of blood glucose by increasing hepatic glucose uptake; antidiabetic agents; obesity | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-7902200-B2 | 3-[6-(Azetidine-1-carbonyl)pyridin-3-yl]oxy-5-[(3S)-1-methyl-2-oxo-pyrrolidin-3-yl]oxy-N-(5-methylpyrazin-2-yl)benzamide; activates glucokinase leading to decreased glucose threshold for insulin secretion and lowering of blood glucose by increasing hepatic glucose uptake; antidiabetic agents; obesity | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-7902200-B2 | 3-[6-(Azetidine-1-carbonyl)pyridin-3-yl]oxy-5-[(3S)-1-methyl-2-oxo-pyrrolidin-3-yl]oxy-N-(5-methylpyrazin-2-yl)benzamide; activates glucokinase leading to decreased glucose threshold for insulin secretion and lowering of blood glucose by increasing hepatic glucose uptake; antidiabetic agents; obesity | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| EP-2086964-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | Astra Zeneca AB (SE) | 2009-08-12 | — | — | EP | disclosed |
| US-20080171734-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171734-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171734-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2008050101-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | ASTRAZENECA AB (SE) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008050101-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | ASTRAZENECA AB (SE) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171734-A1 | CHEMICAL COMPOUNDS | HK1, GCKR, GCK | CA12 4706/4885CA1 3922/4885CA2 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.